Quantitative PCR (qPCR) and digital PCR (dPCR) are cornerstone technologies in most, if not all, molecular labs. They are used for quantification of certain sequences, be it the expression of a gene, the copy number of a transgene or the viral load. While dPCR enables nucleic acid quantification with superior accuracy and precision compared to qPCR, it also comes with drawbacks, such as increased costs and lower dynamic range and throughput. A thorough understanding of the limits and advantages of these 2 PCR variants is essential in choosing the right application for the research question being faced, especially in the context of a clinical trial with tight regulatory constraints. This talk will describe the intrinsic potential of qPCR and dPCR in clinical research, presenting case studies in the space of SARS-CoV-2 detection and CAR-T studies. For each case study we will elaborate on the rationale for selection of qPCR vs dPCR.